Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0081 vs ReoPro in high-risk PCI patients
2009-012206-39Phase 2Completed
- Sponsor
- Ablynx
- Start
- May 2009
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of caplacizumab in thrombosis, unstable angina, myocardial infarction (MI) and 2 more (2 arms), sponsored by Ablynx. Primary endpoint: Incidence and severity of bleeding within 30 days. Started May 2009; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombosisunstable anginamyocardial infarction (MI)stable anginacoronary arteriosclerosis
Beyond the preview
Go deeper on 2009-012206-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012206-39.